Suppressor of cytokine signalling-2 (SOCS-2) is a member of the suppressor of cytokine signalling family, a group of related proteins implicated in the negative regulation of cytokine action through inhibition of the Janus kinase (JAK) signal transducers and activators of transcription (STAT) signal-transduction pathway1. Here we use mice unable to express SOCS-2 to examine its function in vivo. SOCS-2-/- mice grew significantly larger than their wild-type littermates. Increased body weight became evident after weaning and was associated with significantly increased long bone lengths and the proportionate enlargement of most organs. Characteristics of deregulated growth hormone and insulin-like growth factor-I (IGF-I) signalling, including decreased production of major urinary protein, increased local IGF-I production, and collagen accumulation in the dermis, were observed in SOCS-2-deficient mice, indicating that SOCS-2 may have an essential negative regulatory role in the growth hormone/IGF-I pathway.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Reproductive Sciences Open Access 31 May 2022
Nature Communications Open Access 02 December 2021
Journal of Translational Medicine Open Access 20 August 2021
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Starr, R. et al. A family of cytokine-inducible inhibitors of signalling. Nature 387, 917–921 ( 1997).
Hilton, D. J. Negative regulators of cytokine signal transduction. Cell. Mol. Life Sci. 55, 1568–1577 (1999).
Schoenle, E., Zapf, J., Humbel, R. E. & Froesch, E. R. Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 296, 252–253 ( 1982).
Jones, J. I. & Clemmens, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev. 16, 3–34 (1995 ).
Shobe, L., An, M. R., Frank, S. J. & Lowe, W. L. Developmental regulation of insulin-like growth factor-I and growth hormone receptor gene expression. Mol. Cell. Endocrinol. 152, 125–136 (1999).
Mathews, L. S., Enberg, B. & Norstedt, G. Regulation of rat growth hormone receptor gene expression. J. Biol. Chem. 264, 9905– 9910 (1989).
Kopchick, J. J., Bellush, L. L. & Coschigano, K. T. Transgenic models of growth hormone action. Annu. Rev. Nutrition 19, 437–461 (1999).
Daughaday, W. H. in Endocrinology (ed. DeGroot, L. J.) 303– 329 (W. B. Saunders Company, Philidelphia, 1995).
Quaife, C. J. et al. Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology 124, 40–48 ( 1989).
Wanke, R. et al. Overgrowth of skin in growth hormone transgenic mice depends on the presence of male gonads. J. Invest. Dermatol. 113, 967–971 (1999).
Norstedt, G. & Palmiter, R. Secretory rhythm of growth hormone regulates sexual differentiation of mouse liver. Cell 36, 805–812 (1984).
Yakar, S. et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl Acad. Sci. USA 96, 7324–7329 (1999).
Sjogren, K. et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl Acad. Sci. USA 96, 7088–7092 (1999).
Adams, T. E. et al. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J. Biol. Chem. 273, 1285–1287 (1998).
Favre, H., Benhamou, A., Finidori, J., Kelly, P. A. & Edery, M. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett. 453, 63–66 ( 1999).
Tollet-Egnell, P., Flores-Morales, A., Stavreus-Evers, A., Sahlin, L. & Norstedt, G. Growth hormone regulation of SOCS-2, SOCS-3, and CIS messenger ribonucleic acid expression in the rat. Endocrinology 140, 3693–3704 (1999).
Davey, H. W., McLachlan, M. J., Wilkins, R. J., Hilton, D. J. & Adams, T. E. STAT5b mediates the growth hormone-induced expression of SOCS-2 and SOCS-3 mRNA in the liver. Mol. Cell. Endocrinol. 158, 111–116 ( 1999).
Ram, P. A. & Waxman, D. J. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem. 274, 35553–35561 (1999).
Hansen, J. A., Lindberg, K., Hilton, D. J., Nielsen, J. H. & Billestrup, N. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol. Endocrinol. 13, 1832–1843 (1999).
Matsumoto, A. et al. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol. Cell. Biol. 19, 6396–6407 (1999).
Dey, B. R., Spence, S. L., Nissley, P. & Furlanetto, R. W. Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J. Biol. Chem. 273, 24095–24101 (1998).
Lopaczynski, W. Differential regulation of signaling pathways for insulin and insulin- like growth factor I. Acta Biochim. Pol. 46, 51–60 (1999).
Starr, R. et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signalling-1. Proc. Natl Acad. Sci. USA 95, 14395–14399 ( 1998).
Alexander, W. S., Metcalf, D. & Dunn, A. R. Point mutations within a dimer interface homolgy domain of c-mpl induce constitutive receptor activity and tumorigenesis. EMBO J. 14, 5569–5578 ( 1995).
Alexander, W. S., Roberts, A. W., Nicola, N. A., Li, R. & Metcalf, D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood 87 , 2162–2170 (1996).
We thank N. Sprigg, J. Mighall, S. Mifsud and L. DiRago for technical assistance; K. Hanzinikolas for animal care; S. Mihajlovic for histology; and F. Koentgen, L. Barnett, J. DeWinter and M. Swift of the Walter and Eliza Hall Institute Genetically Modified Mouse Facility and T. Adams for discussions and critical assessment of the manuscript. This work was supported by the National Health and Medical Research Council, Canberra, the Anti-Cancer Council of Victoria, an Australian Government Cooperative Research Centres Program Grant, the National Institutes of Health, Bethesda, the J. D. and L. Harris Trust and AMRAD Operations Pty Ltd, Melbourne.
About this article
Cite this article
Metcalf, D., Greenhalgh, C., Viney, E. et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405, 1069–1073 (2000). https://doi.org/10.1038/35016611
This article is cited by
Reproductive Sciences (2022)
Journal of Translational Medicine (2021)
Nature Communications (2021)
Reviews in Endocrine and Metabolic Disorders (2021)